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Abstract
Background: There are few studies evaluating long-term glycemic control using a dipeptidyl peptidase-4 inhibitor
in type 2 diabetes patients with end-stage renal disease (ESRD). The aim of this study was to evaluate the safety
and efficacy of vildagliptin therapy over 2 years in type 2 diabetes with ESRD.
Methods: Patients with ESRD resulting from type 2 diabetes requiring dialysis who had ≥20 % glycated albumin
(GA) were enrolled. Vildagliptin 50 mg once daily was administered for 2 years. Changes in GA and dry weight were
evaluated.
Results: In 32 patients (24 men and 8 women) aged 68.3 ± 1.9 years, vildagliptin 50 mg once daily was
administered for 2 years, but the dose was increased to 50 mg twice daily in 15 patients. GA was significantly reduced
by 2.6 ± 0.6 %, from 22.4 ± 0.6 % at baseline to 19.8 ± 0.4 % at 2 years. After 2 years of vildagliptin therapy, 15 (46.9 %)
of 32 patients achieved a GA level of <20 %. Dry weight changed slightly, with an increase of 1.3 ± 0.8 kg at 2 years. No
adverse drug reactions related to treatment with vildagliptin were seen.
Conclusions: Vildagliptin is a promising therapeutic option for safe, effective glycemic control in type 2 diabetic
patients with ESRD.
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Background
Diabetes is a risk factor for chronic kidney disease, and
strict glycemic control in the management of diabetes
can slow the progression of nephropathy [1]. Nonethe-
less, the number of patients with end-stage renal disease
(ESRD) requiring hemodialysis is increasing linearly in
Japan, and diabetic nephropathy accounts for ≥40 % of
the underlying disease [2]. Therefore, prevention of the
progression of chronic kidney disease in diabetic patients
is a clinical and social problem that must be addressed.
On the other hand, it has been reported that persistent
hyperglycemia is also correlated with increased mortality
in type 2 diabetic patients with ESRD, and strict glycemic
control contributes to reduced mortality in this group [3].
However, since glucose metabolism is modified by
renal function, hypoglycemia often occurs in the treat-
ment of diabetic patients with ESRD. Hypoglycemia is a
risk factor for cardiovascular disease as well as dementia,
and the importance of avoiding hypoglycemia in antidia-
betic therapy was reconfirmed by the results of the
ACCORD study [4]. Nine categories of drugs, including
insulin and glucagon-like peptide-1 receptor agonists, are
available for the treatment of type 2 diabetes. However,
since the pharmacokinetics of these drugs are affected by
renal function, their use is limited in diabetic patients with
ESRD [5]. Only insulin and some oral antidiabetic agents
are available for the treatment of these patients, often
complicating the process of treatment selection.
Dipeptidyl peptidase-4 (DPP-4) inhibitors lower blood
glucose by enhancing the effect of incretin to stimulate
insulin secretion in a glucose-dependent manner as well
as by inhibiting paradoxical glucagon secretion [6]. Des-
pite their recent clinical introduction, DPP-4 inhibitors,
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which are associated with a lower risk of drug-induced
weight gain and a low incidence of hypoglycemia, now play
a central role in the treatment of type 2 diabetes mellitus
[7]. DPP-4 inhibitors can be administered in the presence
of ESRD, and it is believed that their long-term use is safe.
In a pharmacokinetic study of the DPP-4 inhibitor
vildagliptin in patients with renal dysfunction, the expos-
ure level increased with the severity of renal impairment
compared with that in healthy individuals, and therefore
the dose level of 50 mg once daily was recommended for
patients with renal dysfunction [8]. Although the standard
dose of vildagliptin is 50 mg twice daily, vildagliptin
significantly reduced HbA1c at a dose of 50 mg once
daily in a Japanese study [9]. These findings indicate
that vildagliptin can be used in patients with ESRD if
the dose is adjusted.
Since it is not appropriate to evaluate efficacy on a
short-term basis alone, the present study was designed
to evaluate the safety and efficacy of vildagliptin-based
therapy over 2 years in a prospective, open-label study.
To avoid hypoglycemia, previous drugs were replaced
with vildagliptin 50 mg once daily as the initial dose. In
addition, the glycated albumin (GA) level was used as
the parameter of blood glucose control instead of
HbA1c, which is an informative measure of blood glu-
cose levels but may underestimate glycemic control in
patients with renal dysfunction [10].
Methods
Patients
Type 2 diabetic patients receiving hemodialysis 3 times a
week in Shinsen Ikebukuro Clinic, during the period
from April 2010 to March 2011 were included in the
study. Patients who met all of the following criteria were
eligible for study enrollment: 1) ESRD requiring dialysis
resulting from type 2 diabetes; 2) a stable dry weight
after ≥3 months of hemodialysis; 3) aged ≥40 years; 4) a
GA level of ≥20 % despite ≥6 months of diet and exercise
therapy or hypoglycemic therapy; and 5) ≥6 months since
the initiation of insulin therapy if applicable. Those who
met any of the following criteria were excluded from the
study: 1) type 1 diabetes; 2) history of ketoacidosis; 3)
severe hepatic dysfunction; 4) cardiovascular disease
within the past 6 months; and 5) malignant tumor.
This study was approved by the institutional review
boards of Shinsen Ikebukuro Clinic, and all patients pro-
vided written informed consent for study participation
after explanations for the necessity of vildagliptin therapy
were given. The study was conducted as an investigator-
initiated study in accordance with the Declaration of
Helsinki and the Ethical Guidelines for Clinical Re-
search established by the Japanese Ministry of Health,
Labor and Welfare [11].
Study design
This was a prospective, open-label study conducted to
evaluate glycemic control and the safety of vildagliptin
therapy in type 2 diabetes patients with ESRD over
2 years. After it was confirmed that each patient had a
stable GA level and dry weight (body weight just after
hemodialysis), vildagliptin therapy was initiated at a dose
of 50 mg once daily after breakfast. Vildagliptin therapy
at a dose of 50 mg twice daily (after breakfast and din-
ner) was also attempted with glycemic control and toler-
ability taken into consideration. Patients undergoing diet
and exercise therapy were treated with vildagliptin alone
(addition group), and those undergoing treatment with
hypoglycemic agents including insulin were switched to
vildagliptin (switch group). After the start of vildagliptin
therapy, the GA level and body weight were measured
monthly, and clinical laboratory tests (mainly, blood and
biochemical testes) were performed as needed.
Statistical analysis
Long-term glycemic control by vildagliptin was evalu-
ated based on the change in GA as the primary end-
point, and the GA level over time was compared
between the 2 vildagliptin treatment groups. To detect
potential modifiers of vildagliptin-induced changes in
GA, single-regression and multiple-regression analyses
were performed with the percentage change from base-
line in GA at 2 years as the dependent variable; age, dur-
ation of diabetes, duration of dialysis, body mass index
(BMI), and baseline GA were the independent variables.
The data referred showed that vildagliptin 50 mg qd
reduced by 0.78 % in HbA1c from baseline Since the
required number of patients was calculated as 21 to de-
tect this difference with 1.2 in standard deviation under
5 % alpha levels and 80 % power. Thirty patients were
considered to be required for 2-year evaluation.
Values were expressed as mean ± standard error, and
changes in GA, dry weight, or BMI were subjected to
analysis of variance (ANOVA) and multiple comparison
versus baseline using Dunnett’s test. JMP 11 software (SAS
Institute, Tokyo, Japan) was used for statistical analyses.
Results
Baseline characteristics and changes in antidiabetic
therapy
The baseline characteristics of the 32 patients enrolled
and followed up are shown in Table 1. They comprised
24 men and 8 women, aged 68.3 ± 1.9 years. Of the 32
patients, 9 received vildagliptin in addition to diet and
exercise therapy alone, and 1 patient received vildaglip-
tin in addition to voglibose (0.9 mg). The remaining 22
patients were switched from previous antidiabetic agents
to vildagliptin, including 5 patients who were switched
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from insulin. The antidiabetic agents replaced with vilda-
gliptin are listed in Table 2.
During the 2-year follow-up, no patient was addition-
ally treated with insulin, but the dose of vildagliptin was
increased from 50 mg to 100 mg in 15 patients (5 in the
addition group and 10 in the switch group). Of the 15
patients whose dose of vildagliptin was increased, 5 were
additionally treated with mitiglinide (15 mg in 1 patient
and 30 mg in 4 patients) and 1 was additionally treated
with pioglitazone (30 mg). In 17 patients (5 in the addition
group and 12 in the switch group), treatment with 50 mg
of vildagliptin alone was maintained for 2 years.
Glycemic control
GA over time in all patients is shown in Fig. 1a. GA was
significantly reduced by 2.6 ± 0.6 %, from 22.4 ± 0.6 % at
baseline (before vildagliptin therapy) to 19.8 ± 0.4 % at
2 years. In the addition group, GA was markedly reduced
by 4.2 ± 0.8 %, from 24.5 ± 0.8 % at baseline to 20.3 ± 0.8 %
at 2 years (Fig. 1b). GA was also significantly reduced from
baseline in the switch group, but only by 1.9 ± 0.7 % at
2 years (Fig. 1b).
After 2 years of vildagliptin therapy, 15 (46.9 %) of 32
patients achieved a GA level of <20 %. GA was decreased
in all 10 patients who had a GA of ≥24 % at baseline, and
8 of the 10 achieved a GA level of <24 % at 2 years.
In single-regression analysis of the percentage change
in GA after 2 years of vildagliptin therapy in relation to
age, duration of diabetes, duration of dialysis, baseline dry
weight, and baseline GA, the change was positively corre-
lated with the duration of dialysis (r = 0.46, p = 0.02) and
negatively correlated with baseline GA (r = −076, p < 0.01,
Table 3). In multiple-regression analysis of the percentage
change in GA level at 2 years in relation to the duration of
dialysis and baseline GA level, only baseline GA level was
a significant factor (p < 0.01, Table 3).
Change in dry weight and adverse reactions
At the start of vildagliptin therapy, BMI in all patients
was 22.6 ± 0.6 kg/m2, and dry weight was 58.8 ± 2.5 kg.
Weight increased slightly over 2 years of vildagliptin
therapy (Fig. 2), with an increase of 1.3 ± 0.8 kg at 2 years.
Safety
No adverse drug reaction related to vildagliptin includ-
ing abnormal changes on clinical examinations was
noted during the 2-year treatment period.
Discussion
In type 2 diabetic patients with ESRD, good glycemic
control was maintained with little change in dry weight
during 2-year vildagliptin therapy.
According to the Japan Diabetes Society, the target
HbA1c level is <7.0 % for glycemic control to prevent
complications of type 2 diabetes, and the goal should be
glycemic normalization (HbA1c <6.0 %) if possible [12].
Many clinical studies showed that microangiopathy can
be prevented with an HbA1c level of <7.0 %, and it is
extremely challenging to achieve that target without weight
gain or hypoglycemia. On the other hand, since few clinical
studies have been conducted in type 2 diabetic patients
with ESRD, no target glycemic control has been defined
for them, although strict glycemic control may be required
given complications such as retinopathy or neuropathy.
Vildagliptin was chosen as the current study drug
because only two DPP-4 inhibitors, sitagliptin and vilda-
gliptin, were available in Japan when this study was
planned. It was believed that vildagliptin was more suit-
able for type 2 diabetic patients with ESRD than sitagliptin
by comparing their pharmacokinetics in patients with
renal failure [8, 13], and two vildagliptin doses were avail-
able, indicating that dose adjustment would be possible.




Age (years) 68.3 ± 1.9
BMI (kg/m2) 22.6 ± 0.6
Duration of diabetes (years) 20.0 ± 2.0
Duration of hemodialysis (months) 39.9 ± 6.9
GA level at baseline (%) 22.4 ± 0.6
BMI, body mass index; GA, glycated albumin. Values are mean ± standard error
















Gliclazide (20) + voglibose (0.6) 1
Mitiglinide (30) + voglibose (0.9) 1
Nateglinide (60) + pioglitazone (30) 1
Numbers in parentheses are the dose of each agent (mg or IU)
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DPP-4 inhibitors, which have been shown in meta-
analysis to be associated with a low incidence of
hypoglycemia and little risk of weight gain [14, 15], are
useful to achieve therapeutic targets. In addition, while
antidiabetic agents available for patients with ESRD are
limited, some DPP-4 inhibitors can be administered if the
dose is adjusted. Vildagliptin, alogliptin, and sitagliptin
have been studied in type 2 diabetic patients with ESRD.
In a study of alogliptin, insulin-free patients receiving
or not receiving treatment with mitiglinide or voglibose
were additionally treated with alogliptin (n = 30) to
evaluate efficacy and safety over 48 weeks, and it was
found that HbA1c and GA levels were significantly re-
duced [16]. In another study, patients received alogliptin
for 2 years after withdrawal from previous antidiabetic
agents (n = 13), and both HbA1c and GA levels were re-
duced [17]. In a double-blind study of sitagliptin versus
sulfonylurea (SU), patients received the study drug for
54 weeks after withdrawal from previous antidiabetic
agents (n = 64), and both drugs significantly reduced
HbA1c levels [18]. However, the incidence of adverse
hypoglycemic events tended to be higher with SU, and
serious hypoglycemia was reported in 7.7 % of patients
treated with SU but not in those treated with sitagliptin.
Two studies of vildagliptin administered for 24 weeks
(n = 30) [19] and 6 months (n = 15) [20] were reported.
Both were open-label studies of additional treatment with
vildagliptin versus continued existing drugs and confirmed
the usefulness of vildagliptin.
Since the treatment of type 2 diabetes continues over
time, the long-term safety and efficacy should be evalu-
ated. For the present study, therefore, 2-year follow-up
was selected. Moreover, previous antidiabetic agents, in-
cluding insulin, were replaced with vildagliptin to avoid
the risk of hypoglycemia, although vildagliptin in addition
to previous drugs may be more effective. These conditions
were different from those in previous reports, but the dose
of vildagliptin was increased to 50 mg twice daily in 15
(46.9 %) of 32 patients during the 2-year follow-up. While
the dose increase resulted in a 0.8 % reduction in GA, 5
patients were additionally treated with mitiglinide or
pioglitazone, suggesting that glycemic control cannot be
achieved by vildagliptin alone at a dose of 50 mg once
Fig. 1 Changes in glycated albumin in all patients (a) and subgrouped patients (b). Open circles and closed circles in Fig. 1b indicate addition
group and switch group, respectively. *p < 0.05 vs. baseline in Dunnett’s test. Values are mean ± standard error
Table 3 Single- or multiple-regression analysis
Single analysis Multiple analysis
r p value β p value
Age (years) −0.25 0.18
BMI (kg/m2) −0.25 0.16
Duration of diabetes (years) 0.17 0.38
Dry weight (kg) −0.24 0.18
Duration of hemodialysis (months) 0.46 0.02 0.15 0.28
GA level at baseline (%) −0.76 <0.01 −0.73 <0.01
BMI, body mass index; GA, glycated albumin
Fig. 2 Changes in patient dry weight. Values are
mean ± standard error
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daily in many patients. However, since hypoglycemia did
not occur after the dose increase or addition of other oral
antidiabetic agents, more aggressive treatment may be
possible.
Since GA is highly correlated with the HbA1c level
and is approximately 3-fold the HbA1c level [21], the
Japanese Society for Dialysis Therapy recommends a
target GA level of <20 % for glycemic control in type 2
diabetes with ESRD as a temporary goal and a target GA
level of <24 % in patients with a history of cardiovascu-
lar disease or a risk of hypoglycemia [22]. In the present
study, a GA level of <20 % was maintained in 46.9 % of
patients after 2 years of vildagliptin therapy, and a
reduction of GA at 2 years was found in all patients with
GA ≥24 % at baseline, showing the efficacy of vildaglip-
tin even though it replaced previous antidiabetic agents.
Conclusions
In type 2 diabetic patients undergoing hemodialysis,
vildagliptin-based therapy for 2 years maintained lower
blood glucose level measured by GA and showed no
weight gain and hypoglycemia. Vildagliptin is considered
a promising therapeutic option for type 2 diabetic pa-
tients with ESRD.
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